News

FDA issues emergency use authorization for a third COVID-19 vaccine.

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air^® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.

Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021.

The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.

Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.

On Thursday, January 14 at 7 p.m. ET the CF Foundation will host a live town hall where top questions about the COVID-19 vaccines will be answered by a panel of experts. Register here.